BioNTech (NASDAQ:BNTX) Issues Earnings Results, Misses Estimates By $1.34 EPS

BioNTech (NASDAQ:BNTX) announced its quarterly earnings data on Monday. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34), Briefing.com reports. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the previous year, the firm posted ($0.86) earnings per share. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. BioNTech updated its FY 2024 guidance to EPS.

BioNTech Stock Performance

Shares of BioNTech stock traded down $0.25 on Wednesday, reaching $79.25. The stock had a trading volume of 783,346 shares, compared to its average volume of 702,003. The business’s 50-day moving average price is $87.45 and its two-hundred day moving average price is $90.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $125.83. The stock has a market cap of $18.84 billion, a P/E ratio of 158.50 and a beta of 0.23.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research report on Thursday, August 1st. Evercore ISI initiated coverage on shares of BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price for the company. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen decreased their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $109.00.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.